NovaBridge Biosciences
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving NovaBridge Biosciences now
Current reporting with the operating signal separated from the noise.
NBP: NovaBridge Biosciences - Brokerage Recommendations Chart
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NovaBridge Biosciences ADR NBP
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NovaBridge Biosciences Revenue Breakdown – NASDAQ:NBP
Investors are testing whether NovaBridge Biosciences’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease
Investors are testing whether NovaBridge Biosciences’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.NovaBridge Biosciences: NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.I-Mab changes corporate name to NovaBridge Biosciences
The story matters when it changes NovaBridge Biosciences’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest NBP filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
NovaBridge Biosciences, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →